News

Anatomy of a molecule:
What makes remdesivir unique?

Experts weigh in on the chemistry of the potential SARS-nCoV-2 antiviral
Laurel Oldach
March 17, 2020

The World Health Organization in late January convened experts to discuss experimental therapeutics for patients with the emerging coronavirus with no name, no vaccine and no treatment. The panel reported that “among the different therapeutic options, remdesivir was considered the most promising candidate.”

Within weeks, a clinical trial of the compound was underway in China. Results are expected in April; in the meantime, the outbreak of SARS-nCoV-2, the virus that causes COVID-19, has become a global pandemic.

Remdesivir is a nucleoside analog, one of the oldest classes of antiviral drugs. It works by blocking the RNA polymerase that coronaviruses and related RNA viruses need to replicate their genomes and proliferate in the host body.

The molecule originally was synthesized as part of a screen for inhibitors of the hepatitis C virus RNA polymerase. Its inventors at Gilead Sciences decided to move forward with a different nucleoside analog compound to treat hepatitis C. But RNA-dependent RNA polymerases are conserved between many viruses. Experiments in vitro, in cell culture and in animal models have shown that remdesivir has broad-spectrum activity against RNA viruses, including filoviruses (like the one that causes Ebola) and coronaviruses.

Remdesivir resembles the RNA base adenosine, shown here as a monophosphate.

AMP.jpg

The compound and ATP have some important differences, but some features are very similar. ASBMB Today spoke to medicinal chemist Katherine Seley–Radtke at the University of Maryland, Baltimore County, and structural virologist Craig Cameron at the University of North Carolina, Chapel Hill about what makes the molecule interesting. Click on a feature marked in blue to read their remarks.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Laurel Oldach

Laurel Oldach is a former science writer for the ASBMB.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How antioxidant-enhanced ice cream is changing the game for frozen treats
News

How antioxidant-enhanced ice cream is changing the game for frozen treats

Nov. 12, 2024

University of Wisconsin scientists create a sweet treat with more nutrients and better stability using tannins

Helping underrepresented scientists feel seen
Award

Helping underrepresented scientists feel seen

Nov. 12, 2024

Benjamin Garcia will receive the ASBMB Ruth Kirschstein Diversity in Science Award at the ASBMB Annual meeting, April 12–15 in Chicago.

Plants get a GMO glow-up
News

Plants get a GMO glow-up

Nov. 10, 2024

Lose the prickles. Add bioluminescence. Up the nutrients without the bitter flavor. CRISPR gene editing is opening a new world of genetically modified plants for home growers.

Bananapocalypse – the tricky genetics of a devastating fungus
News

Bananapocalypse – the tricky genetics of a devastating fungus

Nov. 9, 2024

Fusarium oxysporum can infect over 120 plant species. Whether it destroys Cavendish bananas as it did their predecessor depends on the agricultural industry and consumers.

From the journals: MCP
Journal News

From the journals: MCP

Nov. 8, 2024

Young proteins are more likely to be degraded. Full automation speeds up sample preparation. Proteomics sheds light on cancer immune suppression. Read about recent MCP papers on these topics.

Modified pea proteins are shaping the future of meat alternatives
Feature

Modified pea proteins are shaping the future of meat alternatives

Nov. 6, 2024

University of Minnesota scientists use enzymes to mimic beef texture in plant-based protein.